- Information
- AI Chat
Exam 1 NSG 124 Study Test Plan
Pharmacology (NSG 124)
Herzing University
Preview text
NSG 124 Pharmacology
EXAM I Test Plan
Unit 1 Module 1 and 2 Location Student Notes
Assessing Pain and pain management: a. defining goals b. identifying interventions c. evaluating success
NSG124.01.
DEFINING GOALS- THE GOAL OF DRUG THERAPY IS TO PRODUCE
MAXIMUM BENEFIT WITH MINIMAL HARM. *MAXIMIZE THERAPEUTIC
RESPONSES WHILE PREVENTING OR MINIMIZING ADVERSE
REACTIONS*
IDENTIFYING INTERVENTIONS- THE NURSE MUST CONSIDER
DOSAGE AND ROUTE OF ADMINISTRATION AS WELL AS TIMING
(WITH RESPECT TO MEALS AND OTHER DRUGS).
FOUR MAJOR GROUPS:
-DRUG ADMINISTRATION.
-INTERVENTIONS TO ENHANCE THERAPEUTIC EFFECTS.
-INTERVENTIONS TO MINIMIZE ADVERSE EFFECTS AND
INTERACTIONS.
-PATIENT EDUCATION.
EVALUATING SUCCESS- SUMMARY OF MONITORING, EVALUATING
THERAPEUTIC EFFECTS, MINIMIZING ADVERSE EFFECTS AND
INTERACTIONS, AND MANAGING TOXICITY.
THE PATIENT MUST BE EVALUATED FOR:
-THERAPEUTIC RESPONSES.
-ADVERSE DRUG REACTIONS AND INTERACTIONS.
-ADHERENCE TO PRESCRIBED REGIMEN.
-SATISFACTION WITH TREATMENT.
Drug Names a. Generic b. Proprietary
NSG124.01.01 NONPROPRIETARY (GENERIC)- LESS COMPLEX THAN THE
CHEMICAL NAME; FINAL SYLLABULS INDICATE PHARM CLASS. *HAS
ONLY ONE*
PROPRIETARY (BRAND)- NAMES UNDER WHICH A DRUG IS
MARKETED; CREATED BY DRUG COMPANIES. *SINGLE DRUG MAY
HAVE SEVERAL*
Over the Counter Meds a. Assessment b. Education, Medication food interactions
NSG124.01.
x
OTC MEDS:
ASSESSMENT- WHEN USED PROPERLY, THEY PROVIDE RELIEF FOR
MANY ALIMENTS WHILE SAVING CONUSMERS THE EXPENSE AND
INCONVINENCE OF VISITING PERSCRIBER.
EDUCATION- NEWSLETTERS, REFERENCE BOOKS, AND THE
INTERNET.
MEDICATION FOOD INTERACTIONS- MAY RESULT IN TOXICITY
OR THERAPEUTIC FAILURE.
IMPACT OF FOOD ON DRUG ABSORPTION:
-DECREASED ABSORPTION.
-INCREASED ABSORPTION.
-IMPACT ON DRUG METABOLISM.
-IMPACT ON DRUG TOXICITY.
-TIMING.
NOTE ACTUAL FOOD INTERACTIONS
Major Pharmacokinetics Processes: a. Medication absorption b. Medication distribution c. Medication metabolism d. Medication excretion Assessment and Evaluation
NSG 124.01.
x
MEDICATIOIN ABSORPTION- THE MOVEMENT OF A DRUG FROM
SITE OF ADMINISTRATION TO BLOOD; THE RATE DETERMINES HOW
SOON THE EFFECTS WILL BEGIN. *AMOUNT OF ABSORPTION
DETERMINES HOW INTENSE THE EFFECTS WILL BE*
MEDICATION DISTRIBUTION- DRUG MOVEMENT FROM THE
Drug to Drug Interactions a. Adverse effects b. Therapeutic effects c. Enhance or decrease effects
NSG123.01.02 ADVERSE EFFECTS- UNEXPECTED OUTCOMES.
THERAPEUTIC EFFECTS-EXPECTED OUTCOMES.
ENHANCE OR DECREASE EFFECTS-INTERACTIONS THAT CAN
REDUCE OR ENHANCE THE EFFECTS OF THE DRUG.
Toxicities and Assessment Skills a. Adverse Reactions b. Side Effect c. Toxicity d. Allergic Reaction e. Idiosyncratic Effect f. Paradoxical Effect g. Iatrogenic Disease h. Physical Dependence i. Carcinogenic Effect j. Teratogenic Effect Organ Specific a. Hepatotoxic b. QT Interval
NSG124.01.02 ADVERSE REACTIONS- ANY NOXIOUS, UNINTENDED, AND
UNDESIRED EFFECT THAT OCCURS AT NORMAL DRUG DOSES. *WE
DON’T WANT*
SIDE EFFECT- UNAVOIDABLE SECONDARY DRUG EFFECT
PRODUCED AT THERAPEUTIC DOSES.
TOXICITY- THE DEGREE OF DETRIMENTAL PHYSIOLOGICAL
EFFECTS CAUSED BY EXCESSIVE DRUG DOSING.
ALLERGIC REACTION- AN IMMUNE RESPONSE; THERE MUST BE A
PRIOR SENSITIZATION OF THE IMMUNE SYSTEM.
IDIOSYNCRATIC EFFECT- UNCOMMON DRUG RESPONSE
RESULTING FROM A GENETIC PREDISPOSITION. *GENETIC
MALFORMATION*
PARADOXICAL EFFECT- THE OPPOSITE OF THE INTENDED DRUG
RESPONSE. WHAT YOU EXOECT TO SEE, EXPECTED RESPONSE
IATROGENIC DISEASE- A DISEASE THAT OCCURS AS THE RESULT
OF MEDICAL CARE OR TREATMENT. (DISEASE PRODUCED BY
DRUGS).
PHYSICAL DEPENDENCE- A STATE IN WHICH THE BODY HAS
ADAPTED TO DRUG EXPOSURE IN SUCH A WAY THAT ABSTINENCE
SYNDROME WILL RESULT IF DRUG USE IS DISCONTINUED.
CARCINOGENIC EFFECT- ABILITY OF CERTAIN MEDICATIONS AND
ENVIORNMENTAL CHEMICALS TO CAUSE CANCERS.
TETRATOGENIC EFFECT- A DRUG-INDUCED BIRTH DEFECT.
*MEDICINES AND OTHER CHEMICALS CAPABLE OF CAUSING BIRTH
DEFECTS ARE CALLED TERATOGENS*
HEPATOTOXIC-DRUGS THAT UNDERGO METABOLISM BY THE
LIVER AND ARE CONVERTED TO TOXIC PRODUCTS THAT CAN
INJURE LIVER CELLS.
QT INTERVAL-ABILITY OF SOME MEDICATIONS TO PROLONGTHE
QT INTERVAL ON THE ELECTROCARDIOGRAM. *CREATING A RISK
OF SERIOUS DYSRYTHMIAS*
DAYS OR LONGER TO DEVELOP.
BODY WEIGHT AND COMPOSITION: SIGNIFICANT
DETERMINATION OF DRUG EFFECTS.
*DISEASE OF THE KIDNEY OR LIVER; ALTERED ELECTROLYTE
STATUS*
Drug Therapy and Pregnancy and Pediatrics a. Basic considerations b. Adverse Reactions c. Teratogens d. FDA Pregnancy Risk Categories
NSG124.01.04 BASIC CONSIDERATIONS: SOME DRUGS ARE PREGNANCY
RELATED; OTHERS ARE FOR CHRONIC DISORDERS; MOST DRUGS
HAVE NOT BEEN TESTED.
ADVERSE REACTIONS: NOT ONLY ARE PREGNANT PTS SUBJECT
TO THE SAME ADVERSE EFFECTS AS NONPREGNANT PTS; MAY
ALSO SUFFER EFFECTS UNIQUE TO PREGNANCY.
TERATOGENS: MEDICATION THAT CAN AFFECT THE
DEVELOPMENT OF THE FETUS.
FDA PREGNANCY RISK CATEGORIES:
A- REMOTE RISK OF FETAL HARM.
B- SLIGHTLY MORE RISK THAN A.
C- GREATER RISK THAN B.
D- PROVEN RISK FOR FETAL HARM.
X- PROVEN RISK FOR FETAL HARM.
Drug Therapy for older adults & end of life a. Pharmacokinetic changes in Older Adults
NSG124.01.04 PHARMACOKINETIC CHANGES IN OLDER ADULTS:
FROM EARLY ADULTHOOD ON, THERE IS A GRADUAL PROGRESSIVE
DECLINE IN ORGAN FUNCTION; ALTERS ABSORPTION,
DISTRIBUTION, METABOLISM, AND EXCRETION OF DRUGS.
-ABSORPTION.
-DISTRIBUTION.
-METABOLISM.
-EXCRETION.
Drugs for Muscle Spasm & Pain a. Baclofen b. Cyclobenzaprine c. Dantrolene d. Mechanism of Action e. Therapeutic use f. Adverse Effects g. Contraindications & Interactions e. Dose and Route
NSG124.02.
x
BACLOFEN: PROTOTYPE FOR CENTRAL ACTING DRUGS THAT
RELIEVE SPASTICITY; HELPFUL IN RELIEVING SPASM RELATED TO
MULTIPLE SCLEROSIS AND SPINAL CORD INJURIES. *ACTS DIRECTLY
ON THE CNS*
-MECHANISM OF ACTION: ACTS WITHIN THE SPINAL CORD TO
DECREASE HYPERACTIVE REFLEXES INVOLVED IN THE REGULATION
OF MUSCLE MOVEMENT.
- THERAPEUTIC USE: REDUCE SPASTICITY ASSOCIATED WITH
MULTIPLE SCLEROSIS AND SPINAL CORD INJURY; DECREASES
FLEXOR AND EXTENSOR SPASMS AND SUPPRESSES RESISTANCE TO
PASSIVE MOVING.
- ADVERSE EFFECTS: CNS DEPRESANT (DROWSINESS, WEAKNESS,
DIZZINESS AND FATIGUE), WITHDRAWL CAN CAUSE
HALUCINATIONS, IDEATION AND SEIZURES. *OVERDOSE CAN
CAUSE COMA AND RESPIRATORY DEPRESSION*
-CONTRADICTIONS & INTERACTIONS: ALCOHOL AND OTHER CNS
DEPRESSANTS, URINATRY RETENTION, AND PSYCHIATRIC
CONDITIONS.
-ADVERSE EFFECTS: CNS DEPRESSANT, ANTICHOLINERGIC
EFFECTS AND CARDIAC RHYTHM DISTURBANCE.
-CONTRADICTIONS & INTERACTIONS: ANTIDEPRESSANTS
(CONTRADICTED FOR PTS TAKING MONOAMINE OXIDASE; MUST
WAIT TWO WEEKS); SIDE EFFECTS INCLUDE FEVER, SEIZURES, AND
RHABDOMYOLYSIS. ALCOHOL AND OTHER CNS DEPRESSANTS.
-DOSE & ROUTE: ORAL (IMMEDIATE RELEASE-5, 7 & 10 MG),
(EXTENDED RELEASE- 15 & 30 MG), ORAL SUSPENSION (1 MG/ML),
AND TOPICAL CREAM (5%, 20 MG/GM).
DIAZEPAM- MOST FREQUENTLY PRESCRIBED BENZO. *REACTS
DIRECTLY ON THE CNS* METABOLIZED IN THE LIVER; NORMALLY
USED FOR ANXIETY, SIEZURES, MUSCLE SPASMS, ALCOHOL
WITHDRAWL.
Nursing Care for Muscle Relaxants a. Preadministration Assessment b. Administration c. Measures to Enhance Therapeutic Effects d. Adverse Interactions
NSG124.02.01 PREADMINISTRATION ASSESSMENT:
- THERAPEUTIC GOAL: RELIEF OF SIGNS AND SYMPTOMS.
-BASELINE DATA: FOR PT TAKING METAXALONE AND TIZANIDINE,
OBTAIN BASELINE LFT’S.
-IDENTIFYING HIGH-RISK PTS: AVOID CHLORZOXAZONE,
METAXALONE, AND TIZANIDINE IN PTS WITH LIVER DISEASE.
ADMINISTRATION:
-ORAL: ALL CENTRAL SKELETAL MUSCLE REAXANTS.
-PARENTERAL: METHOCARBAMOL AND DIAZEPAM MAY BE GIVEN IV,
IM, AND PO.
MEASURES TO ENHANCE THERAPEUTIC EFFECTS: TREATMENT
PLAN SHOULD INCLUDE APPROPRIATE PHYSICAL MEASURES
(IMMOBILIZATION OF THE AFFECTED MUSCLE, APPLICATION OF
COLD COMPRESSES, WHIRLPOOL BATHS, AND PHYSICAL THERAPY).
ADVERSE INTERACTIONS:
-CAUTION PT TO AVOID CNS DEPRESSANTS SUCH AS ALCOHOL,
BENZO’S, OPIOIDS, AND ANTIHISTAMINES.
-WARN PT ABOUT ABRUPT DISCONTINUATION; CAN CAUSE
WITHDRAWL.
Nursing Care Local & General Anesthetics Topical, Injectable and Inhalation a. Pre-assessment b. Administration c. Ongoing Evaluation & Interventions
NSG124.02.02 TOPICAL: BENZOCAIN, COCAINE, DIBUCAIN, DYCLONINE, LIDOCAINE,
PROMOXINE, PRILOCAINE, TETRACAINE.
PREASSESSMENT- REDUCTION OF DISCOMFORT ASSOCIATED WITH LOCAL DISORDERS OF THE SKIN AND MUSCOUS MEMBRANES. ESTER-TYPES ARE CONTRAINDICTATED FOR PT WITH A HISTORY OF SERIOUS ALLERGIC REACTIONS TO THESE DRUGS
ADMINISTRATION- APPLY IN THE LOWEST EFFECTIVE DOSAGE TO THE SMALLEST AREA REQUIRED. IF POSSIBLE, AVOID APPLICATION TO THE SKIN THAT ABRADED OR INJURED.
ONGOING EVALUATION- ABSORPTION TO THE GENERAL CIRCULATION CAN CAUSE SYSTEMIC TOXICITY. EFFECTS THE HEART & CNS
INJECTIONS: BUPIVACAINE, CHLOROPROCAINE, LIDOCAINE, MEPIVACAINE, PRILOCAINE, PROCAINE, ROPIVACAINE, TETRACAINE.
PREASSESSMENT-PRODUCTION OF LOCAL ANESTHSIA FOR SURGICAN, DENTAL, AND OBSTETRIC PROCEDURES. ESTER-TYPES ARE CONTRAINDICTATED
ADMINISTRATION- CLEANSE INJECTION SITE, SHAVING SITE WHEN INDICATED, PLACING PT IN POSITION; PERFORMED BY PHYSICIANS, DENTIST, NP’S, AND CRNA’S.
ONGOING EVALUATION- SYSTEMIC REACTIONS, ALLERGIC REACTIONS, LABOR & DELIVERY, SELF-INFLICTRD INJURY, SPINAL HEADACHE, AND URINARY RETENTION.
INHALATION: DESFLURANE, ENFLURANE, ISOFLURANE, NITROUS OXIDE, SEVOFLURANE.
PREASSESSMENT- MEDICATION HISTORY, RESPIRATORY & CARDIOVASULAR FUNCTION, PRE-OP MEDICATIONS.
ADMINISTRATION-FACE MASK, LARYNGEAL MASK AIRWAY, OR TRACHEAL TUBE.
ONGOING EVALUATION- CARDIOVASULAR AND RESPIRATORY SYSTEMS, CNS, GASTRO TRACT, URINARY TRACT, MANAGEMENT OF POST-OP PAIN.
Opioids Antagonist Agents a. Classification of Opioids b. Pharmacologic Action c. Therapeutic Use d. Mechanism of Action e. Adverse Effects
NSG124.02.03 CLASSIFICATION OF OPIOIDS- (NARCOTIC) ANY DRUG, NATURAL
OR SYNTHEITC, THAT HAS ACTIONS SIMILAR TO MORPHINE.
PHARMACOLOGIC ACTION-
THERAPEUTIC USE-
MECHANISM OF ACTION-
ADVERSE EFFECTS-
Opioid Nursing Considerations a. Pre-administration Assessment b. Administration c. Evaluations and Interventions
NSG124.02.
x
PRE-ADMINISTRATION ASSESSMENT- ASSESS PAIN BEFORE ADMINISTRATION AND ONE HOUR LATER; DETERMINE VITAL SIGNS (RR, BP & PULSE); IDENTIFY HIGH RISK PATIENTS.
ADMINISTRATION- ORAL, IM, IV, SUBQ, RECTAL, EPIDURAL, INTRATHECAL, TRANSDERMAL, AND TRANSMUCOSAL. ADJUST DOSAGE TO MEET PT NEEDS
EVALUATIONS & INTERVENTIONS- EVALUATE FOR PAIN CONTROL AFTER 1 HOUR OF ADMINISTRATION; MONITOR RESPIRATIONS. WARN PT ABOUT RESPIRATORY DISTRESS, DROWSINESS, HYPOTENSION, URINARY RETENTION Opioid Antagonists a. Naloxone b. Mechanism of action c. Pharmacologic Effects d. Pharmacokinetics e. Therapeutic Uses f. Prep, Dose and Administration
NSG124.02.
x
NALOXONE (NARCAN):
MECHANISM OF ACTION: A STRUCTURAL ANALOG OF MORPHINE
THAT ACTS AS A COMPETITIVE ANTAGONIST AT OPIOD RECEPTORS,
BLOCKING OPIOID ACTIONS.
PHARMACOLOGIC EFFECTS: IF ADMINISTERED BEFORE, IT BLOCKS
OPIOID REACTIONS, IF ADMINISTERED AFTER, IT REVERSES
Migraine Treatment Agents & Nursing Considerations a. Aspirin Like Drugs b. Mechanism of Action c. Therapeutic Use d. Pharmacokinetics e. Adverse Effects f. Drug Interactions
NSG124.03.
x
A- NAPROXEN & ACETAMENOPHINE.
B- DECREASES THE SEVERITY OF THE HEADACHE.
C- MIGRAINES, OSTEARTHRITIS AND GOUT.
D- PEAKS IN 2 TO 4 HOURS, METABOLIZED IN THE LIVER,
EXCRETED IN THE URINE.
E- CAN CAUSE HEPATITIS, GI BLEEDING, NEPHROTOXICITY.
F- DO NOT CRUSH, ALWAYS GIVE WITH FOOD.
Histamine Agents & Nursing Considerations a. Two Types of Histamines b. Classification c. Mechanism of Action d. Pharmacologic Effects e. Patient concerns across lifespan f. Therapeutic Use g. Adverse Effects
NSG124.03.
x
A. H1 RECEPTOR ANTAGONIST; H2 RECEPTOR ANTAGONIST.
B. 1ST GENERATION & 2ND GENERATION.
C. BLOCKS THE ACTION OF THE HISTAMINE.
D. DECREASES THE MUCOUS SECRETIONS, DECREASES THE
CNS (CNS DEPRESSION), DECREASES NAUSEA.
E. ELDERLY AND CHILD DOSAGE IS DIFFERENT.
F. MILD ALLERGY, SEVERE ALLERGY, MOTION SICKNESS,
INSOMNIA, COMMON COLD.
G. SEDATION, DIZZINESS, NAUSEA & VOMITNG, PALPITATIONS,
URINARY RETENTION.
COX Inhibitors Actions & Effects a. First and Second Generations NSAIDS. b. Mechanism of Action c. Pharmacokinetics d. Therapeutic Uses e. Adverse Effects f. Expected Effects
NSG124.03.
x
A. 1ST AND 2ND GENERATION. 1ST- ASPIRIN & IBUPROFEN. 2ND
-CELEBREX.
B. DECREASES INFLAMMATION, PAIN AND FEVER.
C. ABSORBED RAPIDLY AND COMPLETELY AFTER ORAL
DOSING; PROCESSED IN THE LIVER.
D. DECREASE INFLAMMATION, DECREASE FEVER,
DISMENARIA, DECREASES PLATELET AGGREGATION.
DECREASE THE RISK OF STROKE OR HEART ATTACK.
E. NAUSEA & VOMITING, HEARTBURN, GI BLEEDING,
GASTRIC ULCERATION. (FROM THE INCREASE OF ACID
AND PEPSIN)
F. RELEIIF OF PAIN AND DECREASED FEVER.
Acetaminophen Action & Effects a. Mechanism of Action b. Pharmacokinetics c. Adverse Effects d. Therapeutic Uses e. Drug and Vaccine Interactions f. Acute Toxicity
NSG124.03.
x
A. HAS ANOGESIC AND ANTIPIRETIC (REDUCED FEVER)
B. READILY ABSORBED WITH ORAL DOSING, DISTRIBUTED
THROUGHOUT THE BODY.
C. ADVERSE EFFECTS ARE RARE.
D. RELIEF OF PAIN AND FEVER.
E. ALCOHOL, CUMADIN, CAN DECREASE IMMUNE RESPONSE.
F. LIVER DAMAGE.
Nursing Considerations of NSAIDS & Acetaminophen a. First & Second Generation b. Pre-administration Assessment c. Administration d. Evaluation & Intervention e. Therapeutic Goal f. Minimizing Adverse Interactions
NSG124.03.03 A. A .1ST & 2ND GENERATION.
B. PAIN LEVEL, HOW HIGH IS FEVER, WHERE IS THE PAIN, ARE
THEY AT RISK? COME IN ORAL, TOPICAL, NASAL, IV, IM,
RECTAL. DECREASES FEVER, DECREASES PAIN.
C. TAKE WITH FOOD, DO NOT CRUSH, DISCARD IF EXPIRED OR
SMELLS LIKE VINEGAR, DO NOT EXCEED DOSE.
D. MONITOR BP.
E. FEVER, INFLAMMATION, OR PAIN IS DECREASING.
F. DECREASE GI BY TAKING WITH FOOD, IF THEY GIVE
MAXIMUM DOSE, IT HAS TO BE DISCONTINUED AFTER 10
DAYS.
Nursing Care for Glucocorticoids a. Major Nursing Implications& Pre- Administration Assessment b. Administration and Dosage c. Evaluation and Interventions d. Minimizing Adverse Interactions
NSG124.03.
x
A. SUPRESS ORGAN TRANSPLANT REJECTION, DECREASE
INFLAMMATION, EXTREME ALLERGIES.
B. ORAL, IV, IM, INTRANASAL; 5 TO 60 MG PO PER DAY.
C. COMPARE CURRENT SIGNS AND SYMPTOMS TO PREVIOUS.
MAKE SURE IT IS IMPROVING.
D. 5-60 MG; DECREASE THE RISK OF ADRENAL INSUFFICIENCY,
OSTEOPOROSIS, INFECTION.
a. H2 Receptor Antagonists & Proton Pump Inhibitors b. Pre-Administration Assessment c. Administration d. Measure to Enhance Therapeutic Effects e. Evaluation and Intervention
x2 B. DIAGNOSIS OF PEPTIC ULCER DISEASE, DO THEY HAVE A HISTORY OF RENAL OR HEPATIC DISFUNCTION? C. ORALLY ONLY. D. AVOID CIGARRETTE SMOKING, OTC DRUGS (ASPIRIN), EAT SMALL MEALS DURING THE DAY (EVERY 2 HOURS). E. EDUCATE ON SIGNS AND SYMPTOMS OF A GI BLEED (BLACK STOOLS, COFFEE GROUND VOMITING).
Drugs & Nursing Considerations for Constipations a. Classifications of Laxatives by category & Mechanism of Action b. Indications c. Adverse Effects
NSG124.04.
x
A. BULK FORMING (FIBER), SURFACTANT (STOOL SOFTNER BY
WATER INCREASE), STIMULANT (STIMULATES THE
PERISTISTALIS), OSMOTIC (RETAINS WATER).
B. IBS.
C. MINIMAL ADVERSE EFFECTS.
Emetic Response, Motion Sickness, Diarrhea and Treatment a. Antiemetic Use b. Antiemetic Drugs c. Motion Sickness drugs d. Antidiarrheal Drugs
NSG124.04.
x
A. SUPRESS NASEA AND VOMITING,
B. ZOFRAN.
C. SCOPOLAMINE.
D. OPIOIDS ARE MOST EFFECTIVE, IMMODIUM (2MG), LAMOTO
(5MG).
Other GI Agents for Irritable & Inflammatory Bowel a. Drugs for Irritable Bowel b. Drugs for Inflammatory Bowel c. Prokinetic Agents d. Action e. Therapeutic Uses f. Adverse Effects
NSG124.04.05 A. LOTRONEX.
B. SULFASALAZINE.
C. REGLIN.
D. DECREASE EMESIS OR VOMITING, INCREASE GI MOTILITY.
E. ORAL OR IV, USED FOR DIABETIC GASTRIC PERISIS,
DECREASE GASTRO REFLUX.
F. INCREASE DOSING CAN CAUSE SEDATION AND DIARRHEA,
TARKIVEDYSKINESIA (TWITCING OF THE FACE).
Antiemetics, Motion Sickness Drugs & Antidiarrheals
NSG124.04.05 A. DECREASE EXCESSIVE WATERY STOOLS, LIMONAL AND
IMMODIUM. ZOFRAN.
a. Actions b. Therapeutic Use c. Pharmacokinetics d. Adverse Effects e. Drug Interactions
B. SUPRESS NAUSEA AND DIARRHEA.
C. PROCESSED THROUGH THE LIVER.
D. NO ADVERSE EFFECTS.
E. NO DRUG INTERATIONS.
Exam 1 NSG 124 Study Test Plan
Course: Pharmacology (NSG 124)
University: Herzing University
This is a preview
Access to all documents
Get Unlimited Downloads
Improve your grades
